Literature DB >> 28824746

Treatment of Metabolic Disorders with CB-1 Receptor Inverse Agonists.

Ahmed F Abdel-Magid1.   

Abstract

Entities:  

Year:  2016        PMID： 28824746      PMCID： PMC5560474          DOI： 10.1021/acsmedchemlett.6b00324

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  3 in total

Review 1.  Modulation of the endocannabinoid system: neuroprotection or neurotoxicity?

Authors:  Christopher J Fowler; Maria Luisa Rojo; Antonio Rodriguez-Gaztelumendi
Journal:  Exp Neurol       Date:  2010-03-29       Impact factor: 5.330

Review 2.  CB1 receptor antagonists: new discoveries leading to new perspectives.

Authors:  E Kirilly; X Gonda; G Bagdy
Journal:  Acta Physiol (Oxf)       Date:  2012-05       Impact factor: 6.311

Review 3.  Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data.

Authors:  Kirk A Bronander; Michael J Bloch
Journal:  Vasc Health Risk Manag       Date:  2007
  3 in total
  1 in total

1.  Comparative assessment of antimicrobial, antiradical and cytotoxic activities of cannabidiol and its propyl analogue cannabidivarin.

Authors:  Chiara Russo; Margherita Lavorgna; Roberta Nugnes; Elena Orlo; Marina Isidori
Journal:  Sci Rep       Date:  2021-11-18       Impact factor: 4.379
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.